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Achondroplasia (ACH), the most common form of dwarfism, is an inherited autosomal-dominant chondrodysplasia caused by a gain-of-
function mutation in fibroblast-growth-factor-receptor 3 (FGFR3). C-type natriuretic peptide (CNP) antagonizes FGFR3 downstream
signaling by inhibiting the pathway of mitogen-activated protein kinase (MAPK). Here, we report the pharmacological activity of
a 39 amino acid CNP analog (BMN 111) with an extended plasma half-life due to its resistance to neutral-endopeptidase (NEP) digestion.
In ACH human growth-plate chondrocytes, we demonstrated a decrease in the phosphorylation of extracellular-signal-regulated kinases
1 and 2, confirming that this CNP analog inhibits fibroblast-growth-factor-mediated MAPK activation. Concomitantly, we analyzed the
phenotype of Fgfr3Y367C/þ mice and showed the presence of ACH-related clinical features in this mouse model. We found that in
Fgfr3Y367C/þ mice, treatment with this CNP analog led to a significant recovery of bone growth. We observed an increase in the axial
and appendicular skeleton lengths, and improvements in dwarfism-related clinical features included flattening of the skull, reduced
crossbite, straightening of the tibias and femurs, and correction of the growth-plate defect. Thus, our results provide the proof of concept
that BMN 111, a NEP-resistant CNP analog, might benefit individuals with ACH and hypochondroplasia.Gain-of-function mutations in FGFR3 (MIM 134934) lead
to achondroplasia (ACH [MIM 100800]), hypochondropla-
sia (HCH [MIM 146000]), and thanatophoric dysplasia (TD
[MIM 187600]).1,2 These conditions, all due to increased
signaling of fibroblast-growth-factor-receptor 3 (FGFR3),
are characterized by a disproportionate rhizomelic
dwarfism and differ in severity, which ranges from mild
(HCH) to severe (ACH) and lethal (TD).3 FGFR3 is a key
regulator of endochondral bone growth4 and signals
through several intracellular pathways, including those
of the signal transducer and activator of transcription
(STAT) and mitogen-activated protein kinase (MAPK).
FGFR3 constitutive activation impairs proliferation and
terminal differentiation of the growth-plate chondro-
cytes5 and synthesis of the extracellular matrix. FGFR3
activation is associated with increased phosphorylation
of the STAT and MAPK pathways. Activation of the STAT
pathway was reported in both Fgfr3K644E/þmice6 and
human growth-plate chondrocytes harboring various
FGFR3 gain-of-function mutations.7,8 The role of the
MAPK pathway in mediating FGFR3 activity is illustrated
by the dwarfism of mice with constitutive activation of
MAPK/extracellular-signal-regulated kinase 1 (MEK1)9
and conversely by the overgrowth of long bones and
enlarged foramen magnum (FM) of mice with inactivation
of extracellular-signal-regulated kinases 1 and 2 (ERK1/
2).10 The MAPK signaling pathway is regulated by C-type
natriuretic peptide (CNP).11 Binding of CNP to its receptor,
natriuretic-peptide receptor B (NPR-B), inhibits FGFR3
downstream signaling at the level of Raf-112 (Figure S1,
available online) and thus triggers endochondral1BioMarin Pharmaceutical, Novato, CA 94949, USA; 2Institut National de la
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mice14 and humans15,16 overexpressing CNP. Conversely,
loss-of-function mutations in NPR2 (MIM 108962),
a gene coding for NPR-B, are responsible for dispropor-
tionate dwarfism in mice17 and acromesomelic dysplasia,
Maroteaux type (MIM 602875) in humans.18 Overproduc-
tion of CNP in the cartilage11 or continuous delivery of
CNP through intravenous (IV) infusion19 normalizes the
dwarfism of Fgfr3ach/þmice, suggesting that administration
of CNP at supraphysiological levels is a strategy for treating
ACH. However, given its short half-life (2 min after IV
administration20), CNP as a therapeutic agent is chal-
lenging in a pediatric population because it would require
continuous IV infusion. Because the subcutaneous (SC)
route of administration is preferred over continuous infu-
sion in pediatric individuals, we designed and manufac-
tured BMN 111, a 39 amino acid CNP pharmacological
analog (Figures S1 and S2). BMN 111 mimics CNP pharma-
cological activity and has an extended half-life as a result of
neutral-endopeptidase (NEP) resistance that allows once-
daily SC administration. BMN 111 behaves similarly to
native CNP with regard to signaling through NPR-B, its
affinity to natriuretic-peptide receptor C, and its inability
to activate natriuretic-peptide receptor A at physiological
concentrations (data not shown). In this study, we per-
formed a detailed characterization of the dwarfism-related
clinical features of the Fgfr3Y367C/þ mouse model.21 We
evaluated the pharmacological activity of this CNP analog
by using in vitro, ex vivo, and in vivo systems, including
human growth-plate chondrocytes harboring the FGFR3
c.1138G>A (p.Gly380Arg) gain-of-function mutation andSante´ et de la Recherche Me´dicale Unite´ 781, Universite´ Paris Descartes-
Paris, France
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Figure 1. ACH-Related Clinical Features in Fgfr3Y367C/þ Mice
(A) Fgfr3Y367C/þ mice exhibit a severe dwarfism phenotype. Mice presented are littermates and are 17 days old.
(B) Computed-tomography (CT) scans of Fgfr3Y367C/þ (n¼ 5) and Fgfr3þ/þmice (n¼ 5) (top) and ACH and control human skulls (15 years
of age) (bottom) show a domed skull (arrow) with an anterior crossbite (arrow) in Fgfr3 mutants. CT scans were performed with a
VivaCT40 microscanner (SCANCO Medical, Laboratoire de Biologie Inte´grative du Tissu Osseux, Institut National de la Sante´ et de la
Recherche Me´dicale Unite´ U1059) according to the following protocols: 0.020 mm voxel resolution, 55 kV, sigma 1.5, support 2,
threshold 148, and 150 uA.
(C) MRI analysis of Fgfr3Y367C/þ (n ¼ 4) and Fgfr3þ/þ mice (n ¼ 4) (3 weeks of age) (top) and ACH and control humans (16 years of age)
(bottom) shows medullary and upper-spinal-cord compression (arrow) in a pathological case. After three averages, a repetition time of
1,200 ms (echo time 80 ms), and two dummy scans, the resolution in mice was 0.0078 cm/px 3 0.0078 cm/px 3 625 micron/px for
a matrix size of 2563 2563 32. The total scan time was 30 min. In humans, MRI was performed with a 1.5 tesla (Signa General Electric
Medical Systems, Milwaukee, WI, USA) scanner with the following sequences: FSE T2 (TR/TE: 5,000/108, 3 mm slices, 0.3 mm gap). MRI
was performed without intravenous contrast enhancement. Osirix software was used for postprocessing.
(D) Hematoxylin and eosin (H&E) staining of the growth plate of 2-week-old Fgfr3Y367C/þmice (n¼ 20) shows a decrease in the height of
the hypertrophic (HZ) zone. The area of the Fgfr3Y367C/þ hypertrophic cells is smaller than that of Fgfr3þ/þ cells (arrows). H&E analysis of
the growth plate from a TD (c.1118A>G [p.Tyr373Cys] mutation) fetus (16 weeks of age), from an ACH (c.1138G>A [p.Gly380Arg]
mutation) fetus, and from a control fetus (25 weeks of age) shows a gradient of extremely severe (TD) to moderate (ACH) (arrows) defects
in the growth-plate architecture. The size of the hypertrophic cells from the ACH growth plate is smaller than that of the control cells.
Comparative analyses of human and mouse growth plates shows that the cartilage of Fgfr3Y367C/þmice (n ¼ 30) resembles that of ACH
mice (n ¼ 15) more than that of TD mice (n ¼ 25). The scale bars represent 50 mm.the Fgfr3Y367C/þmouse model21 expressing the c.1100A>G
(p.Tyr367Cys) mutation corresponding to the c.1118A>G
(p.Tyr373Cys) mutation in TD. Experimental animal
procedures and protocols were approved by the French
Animal Care and Use Committee. Human tissues were ob-
tained with parental consent, and samples were collected
and processed in agreement with the guidelines of the
French ethical committee.
In Fgfr3Y367C/þ mice, the mutant allele is expressed at
sites and at levels where Fgfr3 is normally expressed. The
Fgfr3Y367C/þmice displayed a relevant dwarfism phenotype
(Figure 1A). When compared to their wild-type (WT)
littermates, the Fgfr3Y367C/þ mice showed a significant
disproportionate dwarfism: ~50% of the length of the
appendicular skeleton (54% for the femur and 42% for
the tibia) and ~70% of the length of the axial skeleton
(71% for the lumbar vertebra length L4–L6 and 65% for
the nasoanal length) (Table S1). The anterior-posterior
diameter of the skull and the sagittal and lateral diameters
of the FM were ~70% of those of the WT mice (Figure 1BThe American Jouand Table S1). The Fgfr3Y367C/þ mice presented a growth
deficit affecting both endochondral andmembranous ossi-
fication and displayed disproportionate short stature, as
observed in ACH.22 Computed-tomography scans of the
Fgfr3Y367C/þmouse skull showed the presence of an abnor-
mally domed skull and a small snout with an anterior
crossbite; these were comparable to the prominent fore-
head (frontal bossing) and midface hypoplasia observed
in ACH (Figure 1B). Medullary and upper-spinal-cord
compression due to a reduced size of the FM was observed
by MRI in this mouse model, thereby confirming anoma-
lies in cervical vertebrae (Figure 1C). These signs of cervico-
medullary compression due to FM stenosis were similar to
those reported in ACH children (Figure 1C). All these
features are part of the hallmarks of ACH.3,22 Comparative
histological analysis of the distal femoral epiphysis
revealed similar defects in size and growth-plate architec-
ture in both Fgfr3Y367C/þ and ACH-affected mice; reduced
prehypertrophic and hypertrophic zones, a lack of
columnar arrangement, and abnormal shape and smallerrnal of Human Genetics 91, 1108–1114, December 7, 2012 1109
Figure 2. BMN 111 Reduced ERK1/2 Activation in ACH Growth-
Plate Chondrocytes
(A) Control and pathologic human chondrocytes (ACH) were
isolated as described previously24 and treated with BMN 111
(105 M) prior to coincubation with fibroblast growth factor
(FGF) (100 ng/ml FGF18). BMN 111 pretreatment partially
prevented FGF-mediated increase in ERK1/2 phosphorylation
(n ¼ 6). The cell lysates were subjected to SDS polyacrylamide-
gel electrophoresis and were hybridized overnight at 4C with
phosphorylated-ERK1/2 antibody (1/1,000) (Cell Signaling Tech-
nology, Danvers, MA, USA) or ERK1/2 antibody (1/1,000) (Cell
Signaling Technology). A secondary antibody coupled to peroxi-
dase was used at a dilution of 1:10,000 (GE Healthcare Life
Sciences, Pittsburgh, PA, USA). Bound proteins were detected by
enhanced chemiluminescence (GE Healthcare Life Sciences).
(B) Immunoblot showing STAT3-P and STAT3 (dilution 1:1,000,
Cell Signaling Technology) in human ACH growth-plate chondro-
cytes (n ¼ 3). The phosphorylation of STAT3 did not appear
decreased upon BMN 111 coincubation.hypertrophic cells were observed (Figure 1D). The
c.1118A>G (p.Tyr373Cys) mutation (RefSeq accession
number NM_000142.4) that causes TD in humans trig-
gered in Fgfr3Y367C/þ mice a phenotype that appeared
closer to ACH than to TD (Figure 1D). All these data
allowed us to conclude that this Fgfr3Y367C/þ mouse
model appears to properly recapitulate the human ACH
phenotype.
We observed NPR-B localization in the proliferative and
hypertrophic zones of human control, ACH, and TD
growth plates (data not shown). The pattern of NPR-B
localization in human controls was similar to that of WT
mice.23 We then evaluated in vitro the effect of the CNP
analog, BMN 111, on the ERK1/2 and STAT phosphoryla-
tion levels by using various cell lysates prepared from
human immortalized control chondrocytes (Figure 2A),
primary control chondrocytes (data not shown), and
primary ACH chondrocytes harboring the c.1138G>A
(p.Gly380Arg) mutation (Figure 2A).24,25 The CNP analog
partially inhibited fibroblast-growth-factor (FGF)-mediated
ERK1/2 activation in all human cellular systems tested.
These data were consistent with the inhibition of the
ERK pathway by CNP in rat chondrosarcoma cells.12
Contrariwise, FGF-mediated STAT3 phosphorylation did
not appear decreased in ACH chondrocytes (Figure 2B),
suggesting that NPR-B might not regulate the STAT
pathway in human ACH chondrocytes. Similar observa-
tions were noted in ATDC5 cells in which CNP did not
affect the phosphorylation of STAT1.26 All these data indi-1110 The American Journal of Human Genetics 91, 1108–1114, Dececate that FGFR3 and NPR-B signaling pathways crosstalk in
human ACH chondrocytes through the regulation of the
MAPK signaling pathway. In growth-plate histology
sections of Fgfr3Y367C/þ and Fgfr3þ/þ mice, we observed
FGFR3 and NPR-B localization in the proliferative and
hypertrophic zones of the cartilage (Figure 3A). A similar
distribution pattern was previously observed in WT mice
for FGFR327 and NPR-B.23
The pharmacological activity of BMN 111 was evaluated
ex vivo with the use of femur explants isolated from
Fgfr3Y367C/þmice. At baseline (embryonic day 16.5 [E16.5]),
Fgfr3Y367C/þ femur lengths were slightly shorter than those
of the WT littermates (Figure 3B). Coincubation of the left
femurs with the CNP analog (106 M to 1010 M) for 6 days
led to a significant concentration-dependent increase in
femur size, as illustrated by the gain in femur length
(Figure 3C and Table S2). Increases in bone length were
associated with a concentration-dependent expansion of
the proliferative and hypertrophic zones (Figure S3A).
The correction of the growth-plate size and architecture
was almost complete after coincubation with the 106 M
CNP analog (Figure 3D). We noted the presence of larger
and spherical hypertrophic chondrocytes in the hypertro-
phic zone (Figure 3D). Type X collagen staining, a marker
of chondrocyte differentiation, showed a concentration-
dependent increase in the size of the hypertrophic zone
of the femur explants of Fgfr3Y367C/þ mice and confirmed
the increased number of differentiated chondrocytes
(Figure 3E and Figure S3B). These histological changes
support the proof of concept that BMN 111 promotes
chondrocyte proliferation and differentiation in growth
plates from a mouse model with a FGFR3 gain-of-function
mutation. As improvement in the bone-growth defect
occurred in the absence of any systemic regulation
(ex vivo bone explants), a direct effect on bone growth
was observed. These observations are consistent with
CNP pharmacological activity in control bone explant
cultures from various rodents.28,29
The effectiveness of attenuating the dwarfism pheno-
type of Fgfr3Y367C/þ mice was assessed in vivo. The
Fgfr3Y367C/þ and Fgfr3þ/þ mice were 7 days old when treat-
ment began and received once-daily SC administrations of
BMN 111 for 10 or 20 days. Significant improvement in
dwarfism was noted after 10 days of treatment in
Fgfr3Y367C/þ mice given 240 (not shown) or 800 mg/kg
BMN 111 (Figure 4A) and included an increase in body
size, a longer tail, and a flattening of the skull. After
10 days of treatment, measurement of various segments
(Table 1) in Fgfr3Y367C/þ mice given 240 or 800 mg/kg
revealed a significant dose-dependent growth of the
femur (3.4% or 5.2%, respectively) and nasoanal length
(4.5% or 5.3%, respectively) (p < 0.05). Significant growth
of the tibia (6.6%), anterior-posterior diameter of the
skull (4.8%), and tail (9.8%) (p < 0.05) was observed at
the 800 mg/kg dose level. Mean diameters (sagittal and
lateral) for the FM and atlas vertebra generally appeared
longer for BMN-111-treated mice but did not reachmber 7, 2012
Figure 3. CNP Analog Improved the Size
and Growth-Plate Defect in an Ex Vivo
Fgfr3Y367C/þ Mouse Model
(A) FGFR3 and NPR-B localization in the
proliferative (PZ) and prehypertrophic
(PHZ) zones of the cartilage. Serial his-
tology sections of the growth plate from
Fgfr3þ/þ and Fgfr3Y367C/þ mice (n ¼ 6)
were stained by immunochemistry with
an FGFR3 antibody (1:250 dilution;
Sigma-Aldrich, St. Louis, MO, USA) and
an NPR-B antibody (1:100 dilution; Abcam
[ab14357-ICC/IF/WB], Cambridge, UK)
and were visualized with the Dako Envi-
sion kit with an anti-rabbit antibody
(secondary antibody) (Dako North Amer-
ica, Carpinteria, CA, USA). Images were
captured with an Olympus PD70-IX2-
UCBmicroscope (Olympus, Tokyo, Japan).
(B) A partial normalization of the growth
defect, as well as enlargement of the
epiphysis, was observed in the BMN-111-
coincubated femurs (n ¼ 25) isolated
from Fgfr3Y367C/þ mouse embryos (E16.5)
after 6 days of culture in Dulbecco’s modi-
fied Eagle’s medium with antibiotics and
0.2% bovine serum albumin (Sigma-
Aldrich) supplemented with BMN 111
(BMN 111 patent US2010-0297021, Bio-
Marin Pharmaceutical, Novato, CA, USA).
(C) Quantitative gain in femur length after
coincubation with BMN 111 (106 M to
1010 M) or vehicle. A partial concentra-
tion-dependent restoration of the growth-
plate defect was observed in Fgfr3Y367C/þ
femurs coincubated with BMN 111 (BMN
111 106 M, n ¼ 13; 107 M, n ¼ 10;
108 M, n ¼ 8; 109 M, n ¼ 6; and 1010
M, n¼ 6). *p< 0.05, **p< 0.001, Student’s
t test. Error bars indicate the SD.
(D) H&E staining of longitudinal sections of Fgfr3Y367C/þ (n ¼ 11) and Fgfr3þ/þ (n ¼ 16) femurs coincubated with BMN 111 (106 M) or
vehicle. An increase in the height of the proliferative and hypertrophic zones of the growth plate, along with the normalization of the
shape of the chondrocytes, was observed in BMN-111-treated Fgfr3Y367C/þ femurs. The enlarged regions are boxed. The scale bar in the
‘‘Proximal femur’’ row represents 200 mm, the scale bar in the ‘‘Growth plate’’ row represents 100 mm, and the scale bar in the ‘‘Hyper-
trophic zone’’ row represents 20 mm.
(E) Type-X-collagen (1:30 dilution, Quartett, Berlin, Germany) immunohistochemical staining of the hypertrophic zone of Fgfr3Y367C/þ
femurs coincubated with BMN 111 (106 M) or vehicle. A partial restoration of the size of the hypertrophic zone was observed in BMN-
111-treated Fgfr3Y367C/þ femurs (n¼ 11) compared to vehicle-treated Fgfr3Y367C/þ femurs coincubatedwith vehicle (n¼ 11). The scale bar
represents 100 mm.significance, possibly as a result of the high variability
associated with these parameters (Table 1). Histological
analysis of the distal femur revealed dose-dependent modi-
fications of the size of epiphyses, including a growth-plate
expansion due to increased size of the prehypertrophic and
hypertrophic zones (Figure 4B). An initiation of columnar
arrangement was observed, and the hypertrophic cells
appeared larger with a more spherical shape. The magni-
tude of these phenotypic and histological changes,
observed after only 10 days of treatment, was consistent
with a previous study (Yasoda et al.19) evaluating the effect
of 3 weeks of continuous CNP IV infusion in Fgfr3ach/þ
mice that, compared to Fgfr3Y367C/þ mice, presented with
an attenuated dwarfism phenotype. In the Fgfr3ach/þ
mice, SC administrations of CNP failed to improve bone
growth.19The American JouWe next extended the administration period. The
Fgfr3Y367C/þmice received once-daily SC administrations
(800 mg/kg BMN 111) for 20 days. Treatment was again
initiated at 7 days of age. We observed phenotypic changes
that included flattening of the skull, elongation of the
snout, improvement of the anterior crossbite, larger paws
and digits, and longer and straightened tibias and femurs
(Figure 4C and Figure 4D). The tail was also longer and
had some kinks, suggesting an overdose of BMN 111, as
seen in mice overexpressing CNP (Figure 4D).15 Note-
worthy, Fgfr3-knockout mice30,31 also exhibited over-
growth and tail kinks, consistent with involvement of
the same pathway. The growth-plate-related histological
changes were evident (Figure 4E). A rescue of the height
and architecture of the different zones of the growth plate
was observed. The height of the proliferative zone wasrnal of Human Genetics 91, 1108–1114, December 7, 2012 1111
Figure 4. CNP Analog Partially Corrected the Dwarfism of Fgfr3Y367C/þ Mice
(A) Phenotypic changes were observed in 800 mg/kg BMN-111-treated Fgfr3Y367C/þmice (n ¼ 9) compared to vehicle-treated Fgfr3Y367C/þ
mice (n¼ 9) and included flattening of the skull and an increased length of the long bones and tail. Fgfr3Y367C/þmice received once-daily
SC administrations of BMN 111 or vehicle (0.03 mol/l acetic acid buffer solution, pH 4.0, containing 1% [w/v] benzyl alcohol and 10%
[w/v] sucrose) for 10 days. All mice were dosed approximately 2 hr prior to the dark cycle.
(B) Histological safranin-O (top) or H&E staining of growth plates from Fgfr3Y367C/þmice treated or not with 240 mg/kg or 800 mg/kg BMN
111 during 10 days. Dose-dependent modifications of the epiphysis were observed in distal-femur sections of Fgfr3Y367C/þ mice. The
formation of the secondary ossification center was delayed in vehicle-treated Fgfr3Y367C/þ mice compared to vehicle-treated Fgfr3þ/þ
mice (arrow). CNP analog treatment (800 mg/kg) did not appear to accelerate the ossification process. The scale bars in the ‘‘Cartilage’’
and ‘‘Distal epiphysis’’ rows represent 200 mm, the scale bars in the ‘‘Growth plate’’ row represent 50 mm, and the scale bars in the
‘‘Hypertrophic zone’’ row represent 20 mm.
(C) Pictures of Fgfr3þ/þ (n ¼ 5) and Fgfr3Y367C/þ (n ¼ 5) mice treated during 20 days with 800 mg/kg BMN 111. Phenotypic changes
comprise evident lengthening and straightening of the limbs, as well as longer forelimbs and hind limbs, including paws and digits,
in BMN-111-treated Fgfr3Y367C/þmice (n ¼ 5).
(D) X-rays of the skeleton show flattening of the skull (arrow) and improvement in the snout (arrow) in BMN-111-treated Fgfr3Y367C/þ
mice. X-rays of the hind limbs show straightening of both the tibia and femur in BMN-111-treated Fgfr3Y367C/þ mice (arrows) and
a marked increased in the size of the digits (arrows).
(E) Histological analysis of the distal femur of Fgfr3Y367C/þmice with or without BMN 111 treatment after 20 days. Rescue of the height
and architecture of the different zones of the growth plate, along with replicating and hypertrophic chondrocytes organized in columns,
was observed in BMN-111-treated Fgfr3Y367C/þmice. The shape and size of the proliferative zone, visualized by type-II-collagen (Col II) in-
situ-hybridization labeling (type-II-collagen riboprobe21) and KI67 immunolabeling (KI67 antibody, 1:3,000 dilution, Abcam), were
modified after 800 mg/kg BMN 111 treatment in Fgfr3Y367C/þ mice (arrows). The scale bar in the ‘‘Distal epiphysis’’ row represents
200 mm, and the scale bars in the ‘‘Growth plate,’’ ‘‘Col II,’’ and ‘‘KI67’’ rows represent 50 mm.
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Table 1. Summary of the Percent Increase in the Length of Various Bones or Body Segments andMeasure of the Absolute Length of the FM
and Atlas Vertebra of Fgfr3Y367C/þ Mice Treated with Vehicle or BMN 111 for 10 Days
Fgfr3Y367C/þ
Percent Increase in Length Absolute Length (mm, Mean 5 SD)
Nasoanal
Length Tail
AP
Skull Femur Tibia L4–L6 C0 Sagittal C0 Lateral C1 Sagittal C1 Lateral
Vehicle - - - - - - 2.95 5 0.22
(n ¼ 4)
3.16 5 0.22
(n ¼ 4)
2.37 5 0.10
(n ¼ 4)
2.28 5 0.12
(n ¼ 4)
240 mg/kg
BMN 111
4.5%* no D 2.9% 3.4%* 3.7% 2.8% 2.90 5 0.12
(n ¼ 4)
3.13 5 0.29
(n ¼ 4)
2.45 5 0.11
(n ¼ 3)
2.32 5 0.24
(n ¼ 3)
800 mg/kg
BMN 111
5.3%* 8.0%* 4.8%* 5.2%* 6.6%* 3.3% 3.08 5 0.20
(n ¼ 6)
3.19 5 0.19
(n ¼ 6)
2.41 5 0.20
(n ¼ 6)
2.49 5 0.16
(n ¼ 6)
A dose-dependent (240 or 800 mg/kg) increase in the length of the appendicular and axial skeletons was observed and was significant for the nasoanal length, tail,
anterior-posterior (AP) skull, femur, and tibia (p < 0.05, ANOVA). Absolute lengths of the C0 (foramen magnum [FM]) and C1 (atlas vertebra) (sagittal and lateral
dimensions) were not statistically different between BMN-111-treated and vehicle-treated Fgfr3Y367C/þ mice. Asterisks indicate p < 0.05 with a one-way ANOVA
(Tukey’s post hoc test) comparing BMN-111-treated mice to vehicle-treated mice.increased, as shown by labeling with type II collagen and
KI67 (marker of proliferation); the replicating chondro-
cytes were organized in columns parallel to the long axis
of the bone. In the hypertrophic zone, the terminally
differentiated chondrocytes recovered a columnar align-
ment. The shape and size of the proliferative and hypertro-
phic chondrocytes were corrected (Figure 4E). BMN 111
treatment led to the largest improvement in skeletal
parameters observed to date in a mouse model with an
Fgfr3 gain-of-function mutation.
Herein, we demonstrated that BMN 111, a CNP analog
with an extended half-life due to NEP resistance, counter-
acts constitutive FGFR3 activation, which is the cause of
abnormal cellular proliferation and differentiation in
ACH cartilage. Inhibition of ERK1/2 phosphorylation was
translated in situ into increased bone growth, associated
with a correction of the chondrocyte differentiation, and
normalization of growth-plate architecture. Once-daily
SC administrations of BMN 111 for 20 days improved the
dwarfism of an Fgfr3 mouse model recapitulating ACH.
Amelioration in key relevant ACH clinical features,
including a bowed femur and tibia, anterior crossbite,
and domed skull, was observed. These data support further
development of this CNP analog as an investigational
treatment for ACH and HCH.Supplemental Data
Supplemental Data include three figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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